CN114958766B - Construction method of aging cell model - Google Patents

Construction method of aging cell model Download PDF

Info

Publication number
CN114958766B
CN114958766B CN202210608729.1A CN202210608729A CN114958766B CN 114958766 B CN114958766 B CN 114958766B CN 202210608729 A CN202210608729 A CN 202210608729A CN 114958766 B CN114958766 B CN 114958766B
Authority
CN
China
Prior art keywords
progerin
cells
aging
glu
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210608729.1A
Other languages
Chinese (zh)
Other versions
CN114958766A (en
Inventor
张传茂
王向阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peking University
Original Assignee
Peking University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peking University filed Critical Peking University
Priority to CN202210608729.1A priority Critical patent/CN114958766B/en
Publication of CN114958766A publication Critical patent/CN114958766A/en
Application granted granted Critical
Publication of CN114958766B publication Critical patent/CN114958766B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0625Epidermal cells, skin cells; Cells of the oral mucosa
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00Use of cells in diagnostics
    • C12N2503/02Drug screening
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to the technical field of genetic engineering, in particular to a construction method of an aging cell model. The construction method comprises the following steps: in human skin fibroblasts, the protein progerin is overexpressed. The invention stably expresses protein progerin in human skin fibroblasts by a lentiviral vector transformation method, and constructs an aging cell model showing various aging indexes, which shows obvious phenomena such as DNA damage increase, chromatin abnormality, cell cycle retardation, cell nucleus abnormality, aging-related secretion phenotype increase and the like, and has important significance for scientific research and related drug research and development of presenility, aging-related diseases and other scientific problems.

Description

Construction method of aging cell model
Technical Field
The invention relates to the technical field of genetic engineering, in particular to a construction method of an aging cell model.
Background
There are various existing aging cell models including replicative aging cell models, oncogene-induced aging cell models, stress-type aging cell models, and the like. The replicative senescence cell model is mainly formed by gradually shortening telomeres after continuous division and proliferation of cells through high-frequency passage, and is typically characterized in that: reduced proliferation capacity of cells, cell cycle arrest, etc. Oncogene-induced senescence cell models, which are most typical in Ras expression induction, are characterized by unstable nuclei and gradual degradation. The stress type aging cell model is an aging cell model induced by external stimulus, such as oxidative stress, radiation irradiation, and the like. A typical feature of this model of aging cells is the presence of DNA damage, and the defect in DNA damage repair. The methods of construction of these senescent cell models are relatively complex and, due to the different methods of construction, there are large differences in the senescent phenotype exhibited. In addition, a single type of senescent cell model exhibits relatively few senescent phenotypes and cannot be used as a universal senescent cell model for scientific research and drug development.
The presenilin progerin is produced by alternative splicing following mutation of the gene LMNA, and it causes accelerated senescence, presenilin (Hutchinson-Gilford progeria syndrome), as well as expression during normal senescence. Typical conditions of presenility include a variety of aging-related diseases, such as: alopecia, subcutaneous fat loss, osteoporosis, atherosclerosis, chronic inflammation, tissue and organ fibrosis, myocardial infarction, apoplexy, etc. Thus, presenility is an advantageous tool in studying the mechanisms of aging and in developing anti-aging drugs. So far, the senescent cells of the presenility type are mainly derived from skin cells or blood cells of the presenility patient, and the cell sources are limited.
Due to the factors of small number of presenility patients, inconvenient tissue separation of patient samples, limited in-vitro culture of patient cells and the like, the sources of aging cells of the presenility type are limited, which severely restricts scientific research and drug development of the presenility and the aging-related diseases.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides a construction method of an aging cell model.
In a first aspect, the present invention provides a method for constructing a senescent cell model, comprising:
in human primary cells, the protein progerin is overexpressed.
Aiming at the problems of large difference, less aging phenotype and the like of the existing aging cell model, the invention constructs the aging cell model with various aging phenotypes by expressing presenilin progerin in human primary cells, and specifically comprises the following steps: increased DNA damage, cell cycle arrest, abnormal chromatin, abnormal nuclei, increased senescence-associated secretion phenotypes, and the like. The primary human cells required by the invention can be separated from the skin in a large quantity, and the materials are convenient to obtain and the cost is low.
Further, the human primary cells are human primary skin fibroblasts.
Further, the protein progerin comprises an amino acid sequence shown as SEQ ID NO. 1.
Further, the gene encoding the protein progerin was constructed into lentiviral vectors and then transfected into HK293T cells, and after collection of virus liquid, the human skin fibroblasts were infected.
Further, the gene encoding the protein progerin comprises a nucleotide sequence shown as SEQ ID NO. 2.
Further, the lentiviral vector comprises: pCDH, pQCXIP, pLVX or pLenti 6/TR.
Further, the method further comprises the following steps:
successfully impregnated human skin fibroblasts were screened using a flow cytometer.
The invention further provides an aging cell model constructed by the construction method.
The invention further provides application of the aging cell model in research of aging-related diseases.
Further, the aging-related disease includes one or more of presenility, arteriosclerosis, lipodystrophy, osteoporosis, alopecia, myocardial infarction, stroke, chronic inflammation, pulmonary fibrosis, liver fibrosis, heart fibrosis, kidney fibrosis, or spleen fibrosis.
The invention has the following beneficial effects:
the invention stably expresses protein progerin in human skin fibroblasts and constructs a GFP-progerin aging cell model. The aging cells constructed exhibit a variety of aging indicators including increased DNA damage, abnormal chromatin, cell cycle arrest, abnormal nuclei, increased aging-related secretory phenotypes, and the like. The invention provides a stable and uniform aging cell model, which has important significance for scientific research and related drug research and development of presenility, aging-related diseases and other scientific problems.
Drawings
FIG. 1 is a schematic diagram of the construction method of GFP-progerin senescent cells provided in example 1 of the present invention.
Fig. 2 is a schematic diagram showing the result of cellular immunofluorescence detection of DNA damage marker γh2ax provided in example 2 of the present invention.
FIG. 3 is a schematic diagram showing the result of the cellular immunofluorescence assay of heterochromatin binding protein HP 1. Alpha. Provided in example 2 of the invention.
FIG. 4 is a schematic diagram showing the result of the cellular immunofluorescence assay of heterochromatin marker H3K9me3 according to example 2 of the present invention.
FIG. 5 is a schematic diagram showing the result of the cellular immunofluorescence assay of centromere marker crest provided in example 2 of the present invention.
Fig. 6 is a schematic diagram showing the result of cellular immunofluorescence detection of nuclear pore complex marker nup153 according to example 2 of the present invention.
Fig. 7 is a schematic diagram of western blotting detection result of p16 protein in an presenility patient provided in example 2 of the invention.
FIG. 8 is a schematic diagram showing the Western blotting detection result of p16 in GFP-progerin senescent cells provided in example 2 of the present invention.
FIG. 9 is a schematic diagram showing the results of detection of senescence-associated secretory phenotype genes in a presenility patient according to example 2 of the invention.
FIG. 10 is a schematic diagram showing the results of detection of related secretory phenotype genes of GFP-progerin senescent cell model provided in example 2 of the present invention.
Detailed Description
The following examples are illustrative of the invention and are not intended to limit the scope of the invention.
Reagents and materials referred to in the following examples are commercially available unless otherwise indicated, and the methods of the experiments referred to are all routine in the art unless otherwise indicated.
Example 1
The embodiment provides a method for constructing an aging cell model, which specifically comprises the following steps:
1. experimental materials
And (3) cells: primary human skin fibroblasts (human dermal fibroblasts, HDF), HEK293T (ATCC).
And (3) a carrier: pCDH-CMV-MCS-EF1, psPAX2, pMD2.G, pEGFP-C1.
The medium used was as follows:
common medium: high sugar Dulbecco's Modified Eagle Medium (DMEM) +5-20% fetal bovine serum+100U/mL penicillin+100 μg/mL streptomycin;
virus packaging medium: high sugar Dulbecco's modified Eagle medium (DM EM) +20-40% fetal bovine serum+100U/mL penicillin+100 μg/mL streptomycin.
2. Construction flow
2.1 isolation of human skin fibroblasts
Primary human skin fibroblasts used in the present invention can be isolated by themselves, and commercial products can also be purchased.
The cell separation method is as follows:
first, skin tissue having a diameter of 1mm was removed from the skin of a volunteer, and rinsed 3 times with Phosphate Buffered Saline (PBS); then, removing redundant adipose tissues by using an ophthalmic scissors in an ultra clean workbench, cutting the rest tissues, and washing the rest tissues with PBS for 3 times; then adding 0.1-0.25% pancreatin to submerge all tissue pieces, and placing in a mixture containing 5% CO 2 In a cell incubator of (C) for 5-10min at 37 ℃; after the digestion was completed, the digestion was terminated by adding DMEM medium containing 5-20% fetal bovine serum. Then, the cell mass was blown off by gently repeating the blowing and sucking with a pipette. Finally, the cell suspensions were transferred to 35mm dishes, 4mL of DMED medium containing 5-20% fetal bovine serum, 100U/mL penicillin, 100. Mu.g/mL streptomycin was added, and the mixture was placed in a cell incubator at 5% CO 2 Culturing at 37deg.C for 4-6 days. As the culture proceeds, the medium may be appropriately supplemented according to the amount of the medium in the culture dish.
Finally, the isolated cells are primary human skin fibroblasts. In the whole cell separation process, aseptic operation is ensured, and double antibodies are added into the culture medium to avoid pollution. After the cells are separated, mycoplasma detection is carried out, and after no mycoplasma pollution is determined, the cells can be used for subsequent experiments. To facilitate subsequent experiments, as many HDF cells with low numbers of cryopreservation were performed as possible.
The skin sample of the donor is cut into small pieces by using the ophthalmology, digested by using pancreatin, and then placed in an incubator for culture, and the dissociated cells are skin fibroblasts. The isolated primary human skin fibroblasts (generation 3) were used in this example.
2.2 construction of vectors
(1) Cloning of the coding sequence of human progerin
Total RNA is extracted from blood or skin samples of the presenility patient, then cDNA library is obtained by RT-PCR, and finally the coding sequence is amplified by PCR using progerin primer.
(2) Construction of pCDH-GFP-progerin vector
The coding sequence of GFP was cloned from the pEGFP-C1 vector by PCR, and then the pCDH-CMV-MCS-EF1 vector was cut using double digestion with XbaI and NotI, and the coding sequences of GFP and progerin were inserted, respectively. Wherein GFP is located at the N-terminus of progerin. The vector was sequenced successfully and used in subsequent experiments.
The PCR primer sequences of progerin are as follows:
progerin F:5’-CAGTCTAGAATGGTGAGCAAGGGCGAGGA-3’
progerin R:5’-CAGGCGGCCGCTTACATGATGCTGCAGTTCT-3’。
2.3 viral packaging
HEK293T was passaged into 10cm dishes and 10mL of virus packaging medium was added and then placed in a medium containing 5% CO 2 Is cultured in a cell culture vessel. After the cell density reached 40-70%, the constructed pCDH-GFP-progerin vector and psPAX2, pmd2.G were combined according to 2:1:1 were expressed by transfection using PEI. After 48 hours, cell culture supernatants were collected and pressed as supernatants: PEG-ittM virus sediment = 1:4, and the sediment was added and mixed and placed in a refrigerator at 4 ℃ for overnight sedimentation. The virus particles were then enriched by centrifugation at 1500g for 30min at 4℃and the virus was resuspended in 1mL PBS.
2.4 sorting senescent cells
HDF cells were passaged into 10cm dishes and cultured with 10mL of common medium. When the cell density reaches 40-70%Adding a proper amount of virus infection cells; after 6 hours, the fresh medium was changed. After the culture is continued for 24 to 48 hours, the culture medium in the culture dish is sucked off, and the culture dish is washed with PBS for 2 times, and each time is 2mL; then, the PBS is sucked off, 1mL of pancreatin with the concentration of 0.25% is added, and the culture dish is repeatedly shaken by both hands, so that the pancreatin uniformly infiltrates the bottom of the culture dish; finally, the mixture is placed in a mixture containing 5% CO 2 In a cell incubator of (C) for 1-2min at 37 ℃; taking out the digested cells, adding 0.5mL of common culture medium into a culture dish, and stopping digestion; then repeatedly blowing and sucking by using a pipette, uniformly blowing cells, transferring the cells into a 1.5mL centrifuge tube, and centrifuging at 1000rpm/min for 4 minutes; the supernatant was aspirated, 1mL DMEM was added, gently and repeatedly aspirated, the cells were homogenized, GFP positive cells were sorted by flow sorter, and seeded for expansion. The cells obtained were GFP-progerin senescent cells.
As shown in FIG. 1, green fluorescence represents GFP-progerin, red fluorescence represents lamin labin B1, and blue fluorescence represents chromatin. The results show that the GFP-progerin aging cell is constructed by stably expressing GFP-progerin in normal skin fibroblasts through a lentiviral vector. GFP-progerin senescent cells exhibit abnormal states such as shrinkage of the nuclear membrane, budding of the nuclear membrane, and the like, relative to normal cells.
Example 2
This example is directed to GFP-progerin senescent cells obtained in example 1, and the relevant senescence indicators were detected by cellular immunofluorescence, western immunoblotting and RT-QPCR.
1. By skin fibroblast immunofluorescence experiment, gamma H2AX, HP1 alpha, H3K9me3, crest and nup153 indexes are detected, and the flow is as follows:
(1) GFP-progerin senescent cells were passaged into 35mm petri dishes with coverslips, 3ml of common medium was added and placed in a medium containing 5% CO 2 Culturing at 37 ℃;
(2) When the cell density reached 70-100%, the coverslip was washed 3 times with PBS and then fixed with 4% Paraformaldehyde (PFA) for 20 minutes;
(3) Washing with PBS 3 times, and punching with 2.5% Triton-100 for 5min;
(4) After washing 3 times with PBS, the cells after fixation were labeled with antibodies. Antibodies to Progerin, γh2ax, HP 1a, H3K9me3, crest, nup153 were added to 3% bsa in PBS buffer at a ratio of 1:200, and the fixed cells were back-buckled in primary anti-dilution and incubated overnight at 4 ℃.
(5) The cells after incubation are dipped and washed gently in PBS buffer solution for three times;
(6) According to the corresponding species attribute of the primary antibody, the fluorescent secondary antibody is prepared according to the following formula 1:200 in a 3% BSA buffer, then the fixed cells were back-buckled in a secondary antibody diluent and incubated for 1hr at room temperature.
(7) Mowiol caplets, containing 1 μg/mL DNA dye DAPI and 2.5% of the anti-quencher DABCO, were heat-applied in an oven at 55deg.C in advance. After washing the cells after the secondary antibody incubation with PBS for 3 times, the cells were then back-buckled on thawed 15. Mu.L Mowiol caplets, dried at room temperature in the dark for 1 hour, and microscopic imaging was performed after the caplets were solidified.
(8) Microscopic imaging was performed using a DeltaVision microscope (equipped with an olympus IX-71 inverted microscope, 100×/1.4n.a. oil objective lens, and CCD camera); and the images were processed using the Volocity 6.1.1 software.
The final results of cellular immunofluorescence are shown in FIGS. 2-6, and are specifically as follows:
as shown in FIG. 2, green fluorescence represents progerin, red fluorescence represents DNA damage index γH2AX, and blue fluorescence represents chromatin. The results showed that in Normal skin fibroblasts (Normal cells), the DNA damage marker γh2ax was not detected; in skin fibroblasts (HGPS cells) of the presenility patient, the DNA damage marker γh2ax can be detected significantly; in the constructed GFP-progerin senescent cells (Normal cells+GFP-progerin), the expression of GFP-progerin also leads to an increase in the DNA damage marker γH2AX. These results indicate that the constructed GFP-progerin senescent cells exhibit increased DNA damage.
As shown in FIG. 3, green fluorescence represents progerin, red fluorescence represents heterochromatin binding protein HP 1. Alpha., and blue fluorescence represents chromatin. The results show that heterochromatin binding protein HP 1a can be detected in Normal skin fibroblasts (Normal cells); whereas in skin fibroblasts (HGPS cells) of the presenility patient, heterochromatin binding protein HP 1a is significantly reduced; in the constructed GFP-progerin senescent cells (Normal cells+GFP-progerin), the expression of GFP-progerin also leads to a reduction of the heterochromatin binding protein HP 1. Alpha.s. These results indicate that the constructed GFP-progerin senescent cells exhibit heterochromatin abnormalities.
As shown in FIG. 4, green fluorescence represents progerin, red fluorescence represents heterochromatin marker H3K9me3, and blue fluorescence represents chromatin. The results show that in Normal skin fibroblasts (Normal cells) the heterochromatin marker H3K9me3 can be detected; whereas in skin fibroblasts (HGPS cells) of the presenility patient, the heterochromatin marker H3K9me3 is significantly reduced; in the constructed GFP-progerin senescent cells (Normal cells+GFP-progerin), the expression of GFP-progerin also resulted in a decrease in the heterochromatin marker H3K9me 3. These results indicate that the constructed GFP-progerin senescent cells exhibit heterochromatin abnormalities.
As shown in FIG. 5, green fluorescence represents the presenilin progerin, red fluorescence represents the centromere marker crest, and blue fluorescence represents chromatin. The results show that in Normal skin fibroblasts (Normal cells), the centromere marker crest can be detected; whereas in skin fibroblasts (HGPS cells) of presenility patients, the centromere marker crest is significantly reduced; in constructed GFP-progerin senescent cells (Normal cells+GFP-progerin), GFP-progerin expression also resulted in a decrease in the centromere marker crest. These results indicate that the constructed GFP-progerin senescent cells exhibit abnormal centromeres.
As shown in FIG. 6, green fluorescence represents progerin, red fluorescence represents nuclear pore complex marker nup153, and blue fluorescence represents chromatin. The results showed that in Normal skin fibroblasts (Normal cells), the nuclear pore complex markers nup153 exhibited uniform distribution; whereas in skin fibroblasts (HGPS cells) of the presenility patient, the nuclear pore complex signature nup153 forms aggregates; in the constructed GFP-progerin senescent cells (Normal cells+GFP-progerin), GFP-progerin expression also resulted in the formation of aggregates from the nuclear pore complex markers nup 153. These results indicate that the constructed GFP-progerin senescent cells exhibit abnormal nuclear pore complex localization.
2. The invention further detects the expression of the senescence marker protein p16 by skin fibroblast western blotting, and the specific method is as follows:
(1) GFP-progerin senescent cells were passaged into 35mm dishes, 3ml of common medium was added and placed in a medium containing 5% CO 2 Culturing at 37 ℃;
(2) When the cell density reaches 80-100%, sucking off the culture medium in the culture dish, washing 2 times with PBS (phosphate buffer solution) and 2mL each time; then, the PBS is sucked off, 1mL of pancreatin with the concentration of 0.25% is added, and the culture dish is repeatedly shaken by both hands, so that the pancreatin uniformly infiltrates the bottom of the culture dish; finally, the mixture is placed in a mixture containing 5% CO 2 In a cell incubator of (C) for 1-2min at 37 ℃;
(3) Taking out the digested cells, adding 0.5mL of common culture medium into a culture dish, and stopping digestion; then repeatedly blowing and sucking by using a pipette, uniformly blowing cells, transferring the cells into a 1.5mL centrifuge tube, centrifuging at 1000rpm/min for 4 minutes, and enriching the cells;
(4) Sucking the supernatant, re-suspending the cells with 20-100 μl of PBS, adding equal volume of sample buffer, mixing, and decocting in 95 deg.C vibrator for 10min;
(5) Performing immunoblotting analysis experiment on the obtained sample, preparing 5-12% SDS-PAGE gel, and performing electrophoresis separation on the protein under the condition of 120V constant pressure;
(6) Taking out SDS-PAGE gel after electrophoresis, removing upper concentrated gel, placing in a transfer membrane buffer solution (25mM Tris,192mM glycine and 20% methanol), stacking according to the sequence of sponge, filter paper, nitrocellulose membrane, albumin gel, filter paper and sponge, removing bubbles, clamping by a transfer membrane clamp, and performing wet transfer in the transfer membrane solution for 2 hours under the constant current condition of 300 mA;
(7) After the transfer, the nitrocellulose membrane was taken out and placed in Fast Green dye to preliminarily observe the transfer effect, and then the dye was washed off with TTBS (20 mM Tris-Cl, pH 7.4, 500mM NaCl,0.3%Tween-20). Sealing with 3% skimmed milk diluted in TTBS at room temperature for 30-60min;
(8) After blocking, primary antibodies were labeled overnight at 4deg.C with antibodies to p16, β -actin, GFP (primary antibodies were diluted in TTBS with 3% skim milk, typically at a ratio of 1:500-1:5000);
(9) The next day, the nitrocellulose membrane was washed three times with TTBS for 10min each time; then incubating for 30-60min at room temperature with HRP-conjugated secondary antibody (the secondary antibody is diluted in TTBS containing 3% skimmed milk at a ratio of typically 1:5000-1:20000);
(10) Washing the nitrocellulose membrane with TTBS three times for 10min each time;
(11) Finally, the nitrocellulose membrane coupled with the secondary antibody is reacted with a color development solution, and is exposed and developed in a darkroom by using an X-film negative.
The results are shown in FIG. 7, where β -actin represents an internal control and p16 represents a senescence marker protein. The results showed that the expression of senescence-associated protein p16 was increased in skin fibroblast samples (HGPS) from presenility patients relative to Normal skin fibroblast samples (Normal).
As shown in FIG. 8, β -actin represents an internal control and p16 represents an aging marker protein. The results show that in the constructed GFP-progerin senescent cells, the expression of GFP-progerin results in increased expression of the senescence marker protein p 16. These results indicate that the constructed GFP-progerin senescent cells showed an increase in the senescence marker protein p16, and a cell cycle arrest.
3. The invention further detects the expression of marker genes of five senescence-associated secretion phenotypes of IL1A, IL1B, IL6, IL8 and MMP3 through an RT-QPCR (quantitative PCR) experiment, and the method comprises the following steps:
(1) GFP-progerin senescent cells were passaged into 35mm dishes, 3mL of common medium was added, and placed in a medium containing 5% CO 2 Culturing at 37 ℃;
(2) When the cell density reaches 80-100%, sucking off the culture medium in the culture dish, washing 2 times with PBS (phosphate buffer solution) and 2mL each time; the PBS was then aspirated off and 1mL Trizol was added. The cells were then thoroughly lysed in Trizol by repeated pipetting with a pipette and transferred to a 1.5mL centrifuge tube.
(3) Extracting total RNA according to the operation instruction of Trizol;
(4) Reverse transcription was performed using total RNA, followed by fluorescent quantitative PCR to detect the expression levels of five marker genes IL1A, IL1B, IL6, IL8, MMP 3.
The PCR primer sequences used were as follows:
IL1A-F:5’-TGTAAGCTATGGCCCACTCCA-3’,
IL1A-R:5’-AGAGACACAGATTGATCCATGCA-3’;
IL1B-F:5’-CTCTCTCCTTTCAGGGCCAA-3’,
IL1B-R:5’-GAGAGGCCTGGCTCAACAAA-3’;
IL6-F:5’-CACCGGGAACGAAAGAGAAG-3’,
IL6-R:5’-TCATAGCTGGGCTCCTGGAG-3’;
IL8-F:5’-ACATGACTTCCAAGCTGGCC-3’,
IL8-R:5’-CAGAAATCAGGAAGGCTGCC-3’;
MMP3-F:5’-GGATGCCAGGAAAGGTTCTG-3’,
MMP3-R:5’-CCAGGTGTGGAGTTCCTGATGT-3’。
the results are shown in FIG. 9, where the expression of five senescence-associated secretory phenotype genes, IL1A, IL1B, IL6, IL8, MMP3, was shown to be significantly increased in skin fibroblast samples (HGPS) from presenility patients relative to Normal skin fibroblast samples (Normal).
As shown in FIG. 10, in the constructed GFP-progerin senescent cells, GFP-progerin expression resulted in the expression of five senescence-associated secretory phenotype genes, IL1A, IL1B, IL6, IL8, MMP3, being shown to be significantly increased. These results indicate that the constructed GFP-progerin senescent cells exhibit an increase in the senescence-associated secretory phenotype.
While the invention has been described in detail in the foregoing general description and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that modifications and improvements can be made thereto. Accordingly, such modifications or improvements may be made without departing from the spirit of the invention and are intended to be within the scope of the invention as claimed.
Sequence listing
<110> university of Beijing
<120> method for constructing aging cell model
<130> KHP221114832.4
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 614
<212> PRT
<213> Artificial sequence (Artificial Sequence)
<400> 1
Met Glu Thr Pro Ser Gln Arg Arg Ala Thr Arg Ser Gly Ala Gln Ala
1 5 10 15
Ser Ser Thr Pro Leu Ser Pro Thr Arg Ile Thr Arg Leu Gln Glu Lys
20 25 30
Glu Asp Leu Gln Glu Leu Asn Asp Arg Leu Ala Val Tyr Ile Asp Arg
35 40 45
Val Arg Ser Leu Glu Thr Glu Asn Ala Gly Leu Arg Leu Arg Ile Thr
50 55 60
Glu Ser Glu Glu Val Val Ser Arg Glu Val Ser Gly Ile Lys Ala Ala
65 70 75 80
Tyr Glu Ala Glu Leu Gly Asp Ala Arg Lys Thr Leu Asp Ser Val Ala
85 90 95
Lys Glu Arg Ala Arg Leu Gln Leu Glu Leu Ser Lys Val Arg Glu Glu
100 105 110
Phe Lys Glu Leu Lys Ala Arg Asn Thr Lys Lys Glu Gly Asp Leu Ile
115 120 125
Ala Ala Gln Ala Arg Leu Lys Asp Leu Glu Ala Leu Leu Asn Ser Lys
130 135 140
Glu Ala Ala Leu Ser Thr Ala Leu Ser Glu Lys Arg Thr Leu Glu Gly
145 150 155 160
Glu Leu His Asp Leu Arg Gly Gln Val Ala Lys Leu Glu Ala Ala Leu
165 170 175
Gly Glu Ala Lys Lys Gln Leu Gln Asp Glu Met Leu Arg Arg Val Asp
180 185 190
Ala Glu Asn Arg Leu Gln Thr Met Lys Glu Glu Leu Asp Phe Gln Lys
195 200 205
Asn Ile Tyr Ser Glu Glu Leu Arg Glu Thr Lys Arg Arg His Glu Thr
210 215 220
Arg Leu Val Glu Ile Asp Asn Gly Lys Gln Arg Glu Phe Glu Ser Arg
225 230 235 240
Leu Ala Asp Ala Leu Gln Glu Leu Arg Ala Gln His Glu Asp Gln Val
245 250 255
Glu Gln Tyr Lys Lys Glu Leu Glu Lys Thr Tyr Ser Ala Lys Leu Asp
260 265 270
Asn Ala Arg Gln Ser Ala Glu Arg Asn Ser Asn Leu Val Gly Ala Ala
275 280 285
His Glu Glu Leu Gln Gln Ser Arg Ile Arg Ile Asp Ser Leu Ser Ala
290 295 300
Gln Leu Ser Gln Leu Gln Lys Gln Leu Ala Ala Lys Glu Ala Lys Leu
305 310 315 320
Arg Asp Leu Glu Asp Ser Leu Ala Arg Glu Arg Asp Thr Ser Arg Arg
325 330 335
Leu Leu Ala Glu Lys Glu Arg Glu Met Ala Glu Met Arg Ala Arg Met
340 345 350
Gln Gln Gln Leu Asp Glu Tyr Gln Glu Leu Leu Asp Ile Lys Leu Ala
355 360 365
Leu Asp Met Glu Ile His Ala Tyr Arg Lys Leu Leu Glu Gly Glu Glu
370 375 380
Glu Arg Leu Arg Leu Ser Pro Ser Pro Thr Ser Gln Arg Ser Arg Gly
385 390 395 400
Arg Ala Ser Ser His Ser Ser Gln Thr Gln Gly Gly Gly Ser Val Thr
405 410 415
Lys Lys Arg Lys Leu Glu Ser Thr Glu Ser Arg Ser Ser Phe Ser Gln
420 425 430
His Ala Arg Thr Ser Gly Arg Val Ala Val Glu Glu Val Asp Glu Glu
435 440 445
Gly Lys Phe Val Arg Leu Arg Asn Lys Ser Asn Glu Asp Gln Ser Met
450 455 460
Gly Asn Trp Gln Ile Lys Arg Gln Asn Gly Asp Asp Pro Leu Leu Thr
465 470 475 480
Tyr Arg Phe Pro Pro Lys Phe Thr Leu Lys Ala Gly Gln Val Val Thr
485 490 495
Ile Trp Ala Ala Gly Ala Gly Ala Thr His Ser Pro Pro Thr Asp Leu
500 505 510
Val Trp Lys Ala Gln Asn Thr Trp Gly Cys Gly Asn Ser Leu Arg Thr
515 520 525
Ala Leu Ile Asn Ser Thr Gly Glu Glu Val Ala Met Arg Lys Leu Val
530 535 540
Arg Ser Val Thr Val Val Glu Asp Asp Glu Asp Glu Asp Gly Asp Asp
545 550 555 560
Leu Leu His His His His Gly Ser His Cys Ser Ser Ser Gly Asp Pro
565 570 575
Ala Glu Tyr Asn Leu Arg Ser Arg Thr Val Leu Cys Gly Thr Cys Gly
580 585 590
Gln Pro Ala Asp Lys Ala Ser Ala Ser Gly Ser Gly Ala Gln Ser Pro
595 600 605
Gln Asn Cys Ser Ile Met
610
<210> 2
<211> 1845
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 2
atggagaccc cgtcccagcg gcgcgccacc cgcagcgggg cgcaggccag ctccactccg 60
ctgtcgccca cccgcatcac ccggctgcag gagaaggagg acctgcagga gctcaatgat 120
cgcttggcgg tctacatcga ccgtgtgcgc tcgctggaaa cggagaacgc agggctgcgc 180
cttcgcatca ccgagtctga agaggtggtc agccgcgagg tgtccggcat caaggccgcc 240
tacgaggccg agctcgggga tgcccgcaag acccttgact cagtagccaa ggagcgcgcc 300
cgcctgcagc tggagctgag caaagtgcgt gaggagttta aggagctgaa agcgcgcaat 360
accaagaagg agggtgacct gatagctgct caggctcggc tgaaggacct ggaggctctg 420
ctgaactcca aggaggccgc actgagcact gctctcagtg agaagcgcac gctggagggc 480
gagctgcatg atctgcgggg ccaggtggcc aagcttgagg cagccctagg tgaggccaag 540
aagcaacttc aggatgagat gctgcggcgg gtggatgctg agaacaggct gcagaccatg 600
aaggaggaac tggacttcca gaagaacatc tacagtgagg agctgcgtga gaccaagcgc 660
cgtcatgaga cccgactggt ggagattgac aatgggaagc agcgtgagtt tgagagccgg 720
ctggcggatg cgctgcagga actgcgggcc cagcatgagg accaggtgga gcagtataag 780
aaggagctgg agaagactta ttctgccaag ctggacaatg ccaggcagtc tgctgagagg 840
aacagcaacc tggtgggggc tgcccacgag gagctgcagc agtcgcgcat ccgcatcgac 900
agcctctctg cccagctcag ccagctccag aagcagctgg cagccaagga ggcgaagctt 960
cgagacctgg aggactcact ggcccgtgag cgggacacca gccggcggct gctggcggaa 1020
aaggagcggg agatggccga gatgcgggca aggatgcagc agcagctgga cgagtaccag 1080
gagcttctgg acatcaagct ggccctggac atggagatcc acgcctaccg caagctcttg 1140
gagggcgagg aggagaggct acgcctgtcc cccagcccta cctcgcagcg cagccgtggc 1200
cgtgcttcct ctcactcatc ccagacacag ggtgggggca gcgtcaccaa aaagcgcaaa 1260
ctggagtcca ctgagagccg cagcagcttc tcacagcacg cacgcactag cgggcgcgtg 1320
gccgtggagg aggtggatga ggagggcaag tttgtccggc tgcgcaacaa gtccaatgag 1380
gaccagtcca tgggcaattg gcagatcaag cgccagaatg gagatgatcc cttgctgact 1440
taccggttcc caccaaagtt caccctgaag gctgggcagg tggtgacgat ctgggctgca 1500
ggagctgggg ccacccacag cccccctacc gacctggtgt ggaaggcaca gaacacctgg 1560
ggctgcggga acagcctgcg tacggctctc atcaactcca ctggggaaga agtggccatg 1620
cgcaagctgg tgcgctcagt gactgtggtt gaggacgacg aggatgagga tggagatgac 1680
ctgctccatc accaccacgg ctcccactgc agcagctcgg gggaccccgc tgagtacaac 1740
ctgcgctcgc gcaccgtgct gtgcgggacc tgcgggcagc ctgccgacaa ggcatctgcc 1800
agcggctcag gagcccagag cccccagaac tgcagcatca tgtaa 1845
<210> 3
<211> 29
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 3
cagtctagaa tggtgagcaa gggcgagga 29
<210> 4
<211> 31
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 4
caggcggccg cttacatgat gctgcagttc t 31
<210> 5
<211> 21
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 5
tgtaagctat ggcccactcc a 21
<210> 6
<211> 23
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 6
agagacacag attgatccat gca 23
<210> 7
<211> 20
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 7
ctctctcctt tcagggccaa 20
<210> 8
<211> 20
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 8
gagaggcctg gctcaacaaa 20
<210> 9
<211> 20
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 9
caccgggaac gaaagagaag 20
<210> 10
<211> 20
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 10
tcatagctgg gctcctggag 20
<210> 11
<211> 20
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 11
acatgacttc caagctggcc 20
<210> 12
<211> 20
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 12
cagaaatcag gaaggctgcc 20
<210> 13
<211> 20
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 13
ggatgccagg aaaggttctg 20
<210> 14
<211> 22
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 14
ccaggtgtgg agttcctgat gt 22

Claims (8)

1. A method of constructing a model of senescent cells, comprising:
in human primary cells, the protein progerin is overexpressed;
the amino acid sequence of the protein progerin is shown as SEQ ID NO. 1.
2. The method of claim 1, wherein the human primary cells are human primary skin fibroblasts.
3. The construction method according to claim 2, comprising:
the gene encoding the protein progerin is constructed into a lentiviral vector, then HK293T cells are transfected, and after virus liquid is collected, the human skin fibroblasts are infected.
4. The method according to claim 3, wherein the nucleotide sequence encoding the protein progerin is shown in SEQ ID NO. 2.
5. The method of claim 3, wherein the lentiviral vector comprises: pCDH, pQCXIP, pLVX or pLenti 6/TR.
6. A method of construction according to claim 3, further comprising:
successfully impregnated human skin fibroblasts were screened using a flow cytometer.
7. The senescent cell model constructed by the construction method according to any one of claims 1 to 6.
8. Use of the senescent cell model according to claim 7 in the study of a senescence-associated disease; the study was aimed at non-disease diagnosis and treatment.
CN202210608729.1A 2022-05-31 2022-05-31 Construction method of aging cell model Active CN114958766B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210608729.1A CN114958766B (en) 2022-05-31 2022-05-31 Construction method of aging cell model

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210608729.1A CN114958766B (en) 2022-05-31 2022-05-31 Construction method of aging cell model

Publications (2)

Publication Number Publication Date
CN114958766A CN114958766A (en) 2022-08-30
CN114958766B true CN114958766B (en) 2023-12-26

Family

ID=82957282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210608729.1A Active CN114958766B (en) 2022-05-31 2022-05-31 Construction method of aging cell model

Country Status (1)

Country Link
CN (1) CN114958766B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115044639A (en) * 2022-06-13 2022-09-13 北京大学 Screening method of anti-aging drug
WO2024060269A1 (en) * 2022-09-25 2024-03-28 干细胞转化研究中心有限公司 Mammal-derived cell model and use thereof in screening and/or preparing anti-aging drug, natural product, healthcare food and additive

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014172507A1 (en) * 2013-04-16 2014-10-23 Memorial Sloan-Kettering Cancer Center Age-modified cells and methods for making age-modified cells
CN108187035A (en) * 2018-01-05 2018-06-22 杭州师范大学 Medical usages of the E3 ligases FBW7 in terms of anti-aging and relevant disease
CN112336875A (en) * 2020-08-12 2021-02-09 吴建国 Application of histone deubiquitinating enzyme in preparing anti-aging and anti-aging related diseases medicine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021119217A1 (en) * 2019-12-09 2021-06-17 Wisconsin Alumni Research Foundation Chemical cocktail for inducing senescence in human neurons to promote disease modeling and drug discovery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014172507A1 (en) * 2013-04-16 2014-10-23 Memorial Sloan-Kettering Cancer Center Age-modified cells and methods for making age-modified cells
CN108187035A (en) * 2018-01-05 2018-06-22 杭州师范大学 Medical usages of the E3 ligases FBW7 in terms of anti-aging and relevant disease
CN112336875A (en) * 2020-08-12 2021-02-09 吴建国 Application of histone deubiquitinating enzyme in preparing anti-aging and anti-aging related diseases medicine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Dayle McClintock.The Mutant Form of Lamin A that Causes Hutchinson-Gilford Progeria Is a Biomarker of Cellular Aging in Human Skin.PLoS One.2007,第2卷(第12期),1-10. *
Homo sapiens progerin mRNA, complete cds.GeneBank.2003,1. *
The Mutant Form of Lamin A that Causes Hutchinson-Gilford Progeria Is a Biomarker of Cellular Aging in Human Skin;Dayle McClintock;PLoS One;第2卷(第12期);1-10 *

Also Published As

Publication number Publication date
CN114958766A (en) 2022-08-30

Similar Documents

Publication Publication Date Title
CN114958766B (en) Construction method of aging cell model
JP3070865B2 (en) Subset of human progenitor cells
US20230323352A1 (en) Exosome secreted from gene-modified cells with long non-coding ribonucleic acids and application thereof
CN111925990A (en) Anti-MUC16 CAR-T cell aiming at ovarian cancer and preparation method thereof
CN111073858A (en) YAP1 gene modified mesenchymal stem cell and preparation method thereof
CN108931513B (en) Method and kit for in vitro detection of MUSK-Ab and LRP4-Ab
WO2023241118A1 (en) Anti-senescent drug screening method
CN111925985B (en) Domestication culture method of mesenchymal stem cells
CN113667773A (en) Primer, probe and kit for detecting whether RCL (Rich cell line) pollution exists in CarT cells
CN116574182B (en) Anti-human Ki-67 antibody and preparation method and application thereof
CN117304314A (en) AQP4 antibody and application thereof
CN111154807A (en) Construction method of secretory Laoshan mountain milk goat mammary epithelial cell line
CN113980814B (en) Composition for rapidly lysing peripheral red blood cells and application thereof
WO2021010369A1 (en) Method for detecting circulating tumor cells using virus
US6040144A (en) Procedure for preparing gene expression libraries enriched for secretory protein genes
CN113584116A (en) Detection method for immune regulation and control function of mesenchymal stem cells
CN114441752A (en) Screening method
EP0534619A2 (en) Expression cloning method
CN117487004B (en) Monoclonal antibody against coronavirus S protein and application thereof
CN115947837B (en) Monoclonal antibody HIVmAb771, coding gene and application thereof
CN104774872B (en) Change the method and its application of cell fate
CN112592891B (en) Application of uralensin in-vitro promotion of human adipose-derived mesenchymal stem cell osteogenic differentiation
CN115074388B (en) Mother source factor induced 2C-like pluripotent stem cell and transformation application thereof
CN116082512B (en) Monoclonal antibody for CDKn1A_p21CIP1 protein, and preparation method and application thereof
CN115717155B (en) Recombinant expression vector for replication type virus detection and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant